# Developmental Therapeutics Program

## One Dose Mean Graph

| NSC: 772639 / 1 | Conc: 1.00E-5 Molar | Test Date: Feb 25, 2013 |
|---|---|---|
| Experiment ID: 1302OS30 | | Report Date: May 05, 2013 |

| Panel/Cell Line | Growth Percent |
|---|---|
| Leukemia | |
| CCRF-CEM | 89.90 |
| HL-60(TB) | 94.67 |
| MOLT-4 | 96.41 |
| RPMI-8226 | 94.59 |
| SR | 65.26 |
| Non-Small Cell Lung Cancer | |
| A549/ATCC | 96.80 |
| HOP-62 | 98.56 |
| HOP-92 | 89.24 |
| NCI-H226 | 92.18 |
| NCI-H23 | 97.36 |
| NCI-H322M | 101.46 |
| NCI-H460 | 102.57 |
| NCI-H522 | 43.10 |
| Colon Cancer | |
| COLO 205 | 104.35 |
| HCC-2998 | 99.61 |
| HCT-116 | 98.47 |
| HCT-15 | 80.90 |
| HT29 | 96.61 |
| KM12 | 75.36 |
| SW-620 | 104.81 |
| CNS Cancer | |
| SF-268 | 101.32 |
| SF-295 | 98.18 |
| SF-539 | 92.02 |
| SNB-19 | 97.33 |
| SNB-75 | 101.18 |
| U251 | 89.62 |
| Melanoma | |
| LOX IMVI | 112.04 |
| MALME-3M | 82.58 |
| M14 | 82.70 |
| MDA-MB-435 | 49.91 |
| SK-MEL-28 | 88.99 |
| SK-MEL-5 | 92.00 |
| UACC-257 | 91.89 |
| UACC-62 | 93.90 |
| Ovarian Cancer | |
| IGROV1 | 107.58 |
| OVCAR-3 | 95.35 |
| OVCAR-4 | 104.95 |
| OVCAR-5 | 87.95 |
| OVCAR-8 | 98.73 |
| NCI/ADR-RES | 85.74 |
| SK-OV-3 | 105.89 |
| Renal Cancer | |
| 786-0 | 98.25 |
| A498 | 70.87 |
| ACHN | 96.32 |
| CAKI-1 | 105.02 |
| RXF 393 | 62.55 |
| SN12C | 90.73 |
| TK-10 | 107.69 |
| UO-31 | 89.68 |
| Prostate Cancer | |
| PC-3 | 85.45 |
| DU-145 | 92.44 |
| Breast Cancer | |
| MCF7 | 88.44 |
| MDA-MB-231/ATCC | 91.04 |
| HS 578T | 108.92 |
| BT-549 | 89.41 |
| T-47D | 100.57 |
| MDA-MB-468 | 79.09 |
| Mean | 91.90 |
| Delta | 48.80 |
| Range | 68.94 |

**Mean Growth Percent - Growth Percent**